EXSCEL: No CV Benefit, but No Harm With Bydureon in Diabetes EXSCEL: No CV Benefit, but No Harm With Bydureon in Diabetes

Top-line results from the CV outcomes trial of once-weekly GLP-1 agonist, exenatide for diabetes show there ' s no indication of any CV harm, but there ' s also no benefit.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news